Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Tislelizumab, LBL-007, and BGB-15025 in Patients with Advanced Non-Small Cell Lung Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for Non-Small Cell Lung Cancer, which is a type of lung cancer that can be locally advanced, meaning it has spread to nearby tissues, or metastatic, meaning it has spread to other parts of the body. The study will explore the effects of a medication called Tislelizumab, used in combination with other investigational agents, which are new treatments being tested, with or without chemotherapy. Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells.

The purpose of the study is to assess how well Tislelizumab and the investigational agents work in treating patients with this type of lung cancer. Participants in the study will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will also include a comparison with a placebo, which is a substance with no active medication, to help understand the effectiveness of the treatments being tested.

Throughout the study, participants will be monitored for their response to the treatment, including any changes in their cancer and any side effects they may experience. The study aims to provide valuable information on the potential benefits and risks of using Tislelizumab in combination with other investigational agents for treating Non-Small Cell Lung Cancer.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment

    Upon joining the study, you will be enrolled as a participant. This involves confirming your eligibility based on specific criteria, such as having a diagnosis of non-small cell lung cancer that is advanced or metastatic.

    Your medical history and current health status will be reviewed to ensure you meet the study requirements.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to establish a baseline for your health and the status of your cancer. This may include physical exams, blood tests, and imaging studies.

    The assessment will help in evaluating your response to the treatment throughout the study.

  3. Step 3

    Treatment phase

    You will receive the study treatment, which includes tislelizumab in combination with other investigational agents, with or without chemotherapy. The specific medications and their combinations will be determined by the study protocol.

    The treatment is administered through intravenous infusion, which means the medication is given directly into your vein. The frequency and duration of the treatment will be specified by the study team.

  4. Step 4

    Regular monitoring

    Throughout the study, you will undergo regular monitoring to assess your response to the treatment and to check for any side effects. This includes follow-up visits, blood tests, and imaging studies.

    The study team will evaluate your progress and make any necessary adjustments to your treatment plan.

  5. Step 5

    End of treatment

    Once the treatment phase is completed, a final assessment will be conducted to evaluate the overall response to the treatment.

    You will be informed about the results and any further steps or follow-up care that may be needed.

Who can join the trial?

6 criteria

  • Diagnosis of Non-small Cell Lung Cancer (NSCLC) that is either locally advanced, recurrent, or metastatic. This means the cancer has spread beyond the original site and cannot be treated with surgery or radiation alone.
  • No previous systemic treatment for metastatic NSCLC. However, if you had chemotherapy or radiation for earlier stages of the disease, it must have been completed at least 6 months ago.
  • Your tumor must have been tested for PD-L1 expression, which is a protein that can affect how the immune system responds to cancer. This test can be done on a previous tumor sample or a new biopsy.
  • You must have at least one tumor that can be measured by doctors using specific guidelines called RECIST v1.1.
  • Your overall health should be good, with an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. This is a scale that measures how well you can perform daily activities, with 0 being fully active and 1 being restricted in physically strenuous activity but able to carry out light work.
  • Other specific criteria may apply as defined by the study protocol.

Who cannot join the trial?

10 criteria

  • Patients who have a different type of cancer than Non-small Cell Lung Cancer cannot participate.
  • Patients with cancer that has spread to other parts of the body, known as metastatic cancer, are not eligible.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are not willing or able to follow the study procedures will be excluded.
  • Patients who have other serious health conditions that could interfere with the study treatment are not eligible.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have participated in another clinical trial recently may not be eligible.
  • Patients who have allergies to the study drugs or similar medications will be excluded.
  • Patients who have received certain treatments for their cancer recently may not be eligible.
  • Patients with a history of certain heart conditions or other specific medical issues may be excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Tislelizumab is a type of medication known as an immune checkpoint inhibitor. It works by helping your immune system recognize and attack cancer cells more effectively. In this trial, it is being used to see if it can help treat non-small cell lung cancer when combined with other treatments.

What is already known about the treatment

Tislelizumab – Tislelizumab is administered as an intravenous infusion, meaning it is given directly into the bloodstream through a vein. It is currently being studied in clinical trials for its effectiveness in treating non-small cell lung cancer, particularly in cases where the cancer has spread or cannot be surgically removed. The medication works by helping the immune system recognize and attack cancer cells more effectively. Tislelizumab is classified as an immune checkpoint inhibitor, a type of drug that helps the body's immune system fight cancer.

Investigated diseases

  • Metastatic Non-small Cell Lung Cancer

    This is a type of lung cancer that has spread from the lungs to other parts of the body. It originates in the epithelial cells of the lung and is characterized by uncontrolled cell growth. As the disease progresses, cancer cells can invade nearby tissues and organs. The spread, or metastasis, often occurs to the bones, brain, liver, or adrenal glands. Symptoms may include persistent cough, chest pain, and difficulty breathing. The progression can vary, with some patients experiencing rapid spread while others may have a slower course.

  • Non-small Cell Lung Cancer

    This is the most common type of lung cancer, accounting for about 85% of cases. It begins in the epithelial cells lining the lungs and is characterized by the formation of malignant tumors. The disease progresses as the cancer cells grow and divide uncontrollably, potentially invading nearby tissues. Over time, it can spread to other parts of the body, such as the lymph nodes, bones, or brain. Symptoms often include a persistent cough, shortness of breath, and weight loss. The rate of progression can vary significantly among individuals.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-502738-18-00Protocol codeBGB-LC-201Estimated enrolment214 patientsSponsorBeOne Medicines AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.